Form 4: Rezolute Director Erik Harris Receives Equity Grants

Rezolute, Inc. Director Erik Harris was granted 21,000 restricted stock units and 12,000 stock options on November 19, 2025.

Summary

• Erik Harris, a Director of Rezolute, Inc. (RZLT), reported acquiring equity securities.
• On November 19, 2025, Harris was granted 21,000 common shares in the form of restricted stock units (RSUs) at a price of $0. These RSUs will fully vest on December 1, 2026.
• On the same date, Harris was granted 12,000 Director Stock Options with an exercise price of $10.16. These options also fully vest on December 1, 2026, and have an expiration date of November 19, 2035.
• Following these transactions, Harris directly beneficially owns 21,000 common shares and 12,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a director, which is a standard compensation practice aimed at aligning interests and incentivizing long-term performance. It does not contain information that would significantly alter the company's fundamental outlook, but it does reflect continued commitment from a key board member.

Positives

• The grant of restricted stock units and stock options to Director Erik Harris indicates continued alignment of management interests with shareholder value.
• Equity grants are a common incentive for directors, suggesting confidence in the company's future performance.

Future Outlook

The grants of restricted stock units and stock options with future vesting dates suggest an expectation of continued service and future value creation by the director. The options' exercise price of $10.16 implies a target for future stock performance.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, like Rezolute, Inc., to align long-term interests and incentivize performance. This filing reflects a routine compensation event rather than a strategic industry shift.

Comparison to Industry Standards

• The practice of granting restricted stock units and stock options to directors is a common compensation mechanism across publicly traded companies, particularly in growth-oriented sectors such as biotechnology.
• The vesting schedule (fully vesting on December 1, 2026) is typical for long-term incentive plans, aiming to retain key personnel and align their interests with sustained company performance.
• The exercise price of $10.16 for the stock options would typically be set at the fair market value of the stock on the grant date, which is standard practice to ensure the options provide an incentive for future stock price appreciation.

Related Party Transactions

• The grant of restricted stock units and stock options to Director Erik Harris constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grants align the director's interests with long-term shareholder value creation, as the value of the grants is tied to the company's stock performance. However, future exercise of options or vesting of RSUs could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The restricted stock units and stock options granted to Erik Harris will fully vest on December 1, 2026.
• The stock options have an expiration date of November 19, 2035, allowing for potential exercise in the future.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align interests. It does not provide new fundamental information that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on existing analysis of the company's fundamentals.

Keywords

Rezolute Inc, RZLT, Erik Harris, Director, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Beneficial Ownership